Lv5
1010 积分 2025-05-29 加入
A first-in-class pulsatile FXR agonist for bile-acid-related liver diseases
22天前
已完结
FGF21 synergizes with leptin to counteract obesity-related metabolic comorbidities by reversing hepatic leptin resistance
27天前
已完结
Opportunities and challenges of bi-specific antibodies
29天前
已完结
Emerging small-molecule AKR1C3 inhibitors development for cancer therapy: Progress from 2021 to 2025
1个月前
已完结
Polo-like kinase 1 (PLK1) signaling in cancer and beyond
1个月前
已完结
Endocytic evasion confers resistance to antibody-drug conjugates therapy in cancer
1个月前
已完结
Modular nucleic acid-based construct for delivery of immunostimulatory agonists and oncogene-silencing oligonucleotides in tumours
2个月前
已完结
Re-Evaluating Antibody–Drug Conjugate Linker Stability: Assessment, Interpretation, and Clinical Translation
3个月前
已完结
Mechanisms of resistance to antibody–drug conjugates in cancers
3个月前
已完结
Tumour fatty acid metabolism in the context of therapy resistance and obesity
3个月前
已完结
皖公网安备34019202002308
